Safety of anti-TNFα biological drugs;Sicurezza dei farmaci biologici anti-TNFα

Reumatismo

Volumn 57, Issue SUPPL. 4, 2005, Pages 34-39

  Trotta, F ^a   Valentini, G ^b,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Policlinico   (Italy)

Author keywords

Safety; Side effects; TNF inhibitors; Tumor Necrosis Factor alfa

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ASPERGILLUS; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CRYPTOCOCCUS; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; DRUG SAFETY; GRANULOMA; HISTOPLASMA; HUMAN; INFECTION; INFECTION RISK; LYMPHOMA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; DEMYELINATING DISEASES; HEART FAILURE; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA; OPPORTUNISTIC INFECTIONS; PANCYTOPENIA; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECURRENCE; RHEUMATIC DISEASES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRUS ACTIVATION;

EID: 33846680501     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65: 33-8.
2. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 1538-43.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
4. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
5. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Care Res 2002; 47: 17-21.
6. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-21.
7. Matteson EL. Need for circumspection in prescribing tumor necrosis factor nhibitors and other biologic response modifiers. Arthritis Care Res 2002; 47: 1-4.
8. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
9. Yazici Y. ACR Annual Meeting San Antonio. Arthritis Rheum 2004; 50 (Suppl): abs 701.
10. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22.
11. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
12. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al; PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29: 667-77.
13. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003; 21: 526.
14. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl II): 30-3.
15. Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999; 79: 379-86.
16. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
17. Perez JL ACR Annual Meeting 2004 San Antonio. Arthritis Rheum 2004; 50 (Suppl) abs 1877.
18. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653-6.
19. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8.
20. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70.
21. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
22. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24: 477-82.
23. La Montagna G, Valentini G. Lysteria monocitogenes meningitis in a patient undergoing etanercept treatment Clin Exp Rheumatol 2005; 23: 121.
24. Ferraccioli GF, Gremese E. Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis 2004; 63: 613-5.
25. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63: 1075-8.
26. FDA safety update on TNF antagonists, 15/8/2001, pag. 11.
27. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. CID 2004; 38: 1261-5.
28. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
29. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15: 280-94.
30. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004; 22(Suppl 35): S134-40.
31. US Food and Drug Administration. Safety update on TNF-alfa antagonist: infliximab and etanercept. http://www.fda.gov/ohrms/dokets/ac/01/biefing/3779b 2_01_cber_safety%20_revision2pdf (accessed 10 February 2003).
32. Lock C, Oksenberg J, Steinman L. The role of TNFalpha and lymphotoxin in demyelinating disease. Ann Rheum Dis 1999; 58 (Suppl 1): i 121-8.
33. van der Laken CJ, Lems WF, van Soesbergen RM, van der Sande JJ, Dijkmans BA. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum 2003; 48: 269-70.
34. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001; 358: 1784.
35. ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003; 326: 579.
36. Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003; 42: 702-3.
37. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
38. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
39. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841-50.
40. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
41. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
42. De Rycke LD, Kruithof E, Van Damme N, Hoffman IEA, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathy. Arthritis Rheum 2003; 48: 1015-23.
43. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dalqvist S: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy. Ann Rheum Dis 2005; 64: 403-7.
44. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
45. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80.
46. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J. 2002; 71: 101-5.
47. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002; 11: 753-5.
48. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003; 28: 604-7.
49. Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001; 40: 1317-9.
50. Kent PD, Davis JM 3rd, Davis MD, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-8.
51. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 850-1.
52. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004; 50: 1690-2.
53. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287-91.
54. Fitzcharles MA, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 2002; 29: 2525-30.
55. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041-4.
56. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47: 445-9.
57. Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002; 146: 334-5.
58. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131: 634.
59. Berthelot JM, Glemarec J, Maugars Y, Prost A. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 703-5.
60. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
61. Brand CA, Rowley MJ, Tait BD, Mukden KD, Whittingham SF. Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features. Ann Rheum Dis 1992; 51: 173-6.
62. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
63. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
64. Mann DL, McMurray JJ. Presentation of results of the REINASSANCE, RECOVER and RENEWAL studies Heart failure 2002, Jun 8-11 Oslo, Norway.
65. Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22 (Suppl 35): S141-7.
66. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
67. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003; 48: 1493-9.
68. Marchesoni A, Arreghini M, Panni B, Battafarano N, Uziel L. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology (Oxford) 2003; 42: 193-4.
69. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003; 71: 396-8.
70. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-79.
71. Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004; 50: 1703-6.
72. van Vollenhoven RF. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol 2004; 22 (Suppl 35): S122-5.
73. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
74. Padovan M, Massara A, Rizzo N, Lo Monaco A, Fotinidi M, La Corte R, et al. Dati di safety del trattamento con anti-TNFα in una coorte di 183 pazienti affetti da artrite reumatoide, artrite psoriasica e spondilite anchilosante. Reumatismo 2004; 56 (suppl 2): 388.
75. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1 ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2004; 63 (suppl II): ii2-ii12.
76. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004; 27: 307-24.
77. Schwartzman S, Morgan GJjr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004; 6 (suppl 2): S19-23.